O
Osler Diagnostics
A ground-breaking handheld diagnostic for testing a vast range of biomarkers
About Osler Diagnostics
Osler Diagnostics is a healthcare technology startup that aims to revolutionize global healthcare through its innovative product, the Osler Origin®. This device offers a wide range of tests that can be used in various healthcare settings such as emergency departments, doctor's offices, and retail pharmacies. The company's unique selling proposition lies in its proprietary "lab-in-your-hand" technology, which includes the Osler HemaTap® for sample addition, microfluidic sample preparation, and electrochemical biosensing.
Read full description
The technology behind Osler Origin® is the result of extensive research at Oxford University, followed by years of industrialization by Osler. The company has a robust intellectual property portfolio that protects its unique technology.
Osler Diagnostics operates in the healthcare technology market, serving healthcare providers across different settings. Its business model revolves around the sale of its Osler Origin® device and the tests it offers. The company generates revenue from the sale of these devices and tests to healthcare providers.
The team behind Osler Diagnostics is led by Co-Founder and CEO, Connor Campbell, who has a background in medical sciences and business consultancy. The commercial strategy is overseen by Chief Commercial Officer, Tom Parenteau, who brings over 25 years of experience in global marketing and sales in the healthcare sector.
At a glance
- Status
- Operational
- Founded
- 2016
- Headquarters
- Oxford, United Kingdom
- Employees
- 125
- Open positions
- None listed
- Dealroom signal
- 65.9/100
- Industry
- Health
- Sub-industry
- BioTechnology, Medical Devices, Health Platform
- Sector
- Biotech & Life Sciences, Testing, Biotechnology, Pathology, Health Diagnostics, Spinout
- Technology
- Hardware, Deep Tech
- Business model
- Manufacturing
- Client focus
- b2b, b2c
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES COther financing | Nov 2022 | $98M | $392M | Lansdowne Partners · Braavos Investment Advisers · M&G · Oxford Science Enterprises | ↗ |
| GRANTOther financing | Apr 2022 | $792K | — | Undisclosed | — |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
Growth signals
Latest recorded traffic for Osler Diagnostics is 2.4K monthly website visits, up 140% over the last three months. Osler Diagnostics's team declined 15% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed4 investors entered at this stage
Oxford Technology
Bio-Rad Laboratories
Oxford Science Enterprises
Defence and Security Accelerator
Series A1 investor entered at this stage
Michael Spencer
Series B and later3 investors entered at this stage
Lansdowne Partners
Braavos Investment Advisers
M&G
Other known investors2 additional known investors
Oxford University Innovation
University of Oxford
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Osler Diagnostics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Osler Diagnostics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.